November 15th, 2026Kidney Compass: FIND-CKD Finerenone Data in FSGS and Treatment SequencingHiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.Read more
November 15th, 2026Kidney Compass: GFR Slope and Hierarchical Composite Endpoints in Glomerular DiseaseLesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.Read more
November 14th, 2026Early Dupilumab in Pediatric EoE Tied to Lower Incident AsthmaChildren with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.Read more
November 14th, 2026Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal SyndromeNo patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.Read more
November 14th, 2026Kidney Compass: Platform Trials in IgA Nephropathy and Glomerular DiseaseSuceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.Read more
November 14th, 2026FDA Approves Obinutuzumab (Gazyva) for Primary Membranous NephropathyApproval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.Read more
November 13th, 2026Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect AnalysisA post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.Read more
November 13th, 2026ICONIC-ASCEND: Icotrokinra Tops Placebo, Matches Ustekinumab in PsoriasisOral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.Read more